Key terms

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AMGN news

Apr 11 9:56am ET Early notable gainers among liquid option names on April 11th Apr 03 7:00am ET Analysts’ Top Healthcare Picks: Amgen (AMGN), Intra-Cellular Therapies (ITCI) Mar 25 8:01am ET Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Amgen (AMGN) and Petiq (PETQ) Mar 08 7:30am ET Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Regeneron (REGN) Mar 01 5:10am ET Amgen upgraded to Conviction Buy from Buy at Goldman Sachs Mar 01 1:12am ET Amgen’s Sell Rating Justified by Emerging Competition and Safety Concerns in Obesity Drug Market Feb 29 5:50am ET Analysts’ Top Healthcare Picks: Amgen (AMGN), Sarepta Therapeutics (SRPT) Feb 26 10:06am ET Jefferies biotechnology analyst to hold an analyst/industry conference call Feb 26 9:03am ET Amgen opens state-of-the-art biomanufacturing facility in central Ohio Feb 26 12:01am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), Teleflex (TFX) and Amgen (AMGN) Feb 25 11:30pm ET Balanced Outlook for Amgen: Growth Potential Amidst Challenges and Uncertainties Feb 23 7:26am ET Buy Rating Affirmed: Growth and Expansion in Amgen’s Rare Disease Portfolio Post-Horizon Acquisition Feb 23 5:56am ET Amgen’s Strategic Growth and Market Expansion in Rare Diseases Bolster Buy Rating Feb 23 5:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Alnylam Pharma (ALNY) and Bausch Health Companies (BHC) Feb 23 3:15am ET Barclays Sticks to Their Sell Rating for Amgen (AMGN) Feb 22 3:55pm ET Amgen to host conference call Feb 22 4:55am ET Amgen to host conference call Feb 19 3:39pm ET Amgen to host conference call Feb 19 9:15am ET Amgen (AMGN) Receives a Buy from Wells Fargo Feb 12 1:25pm ET Amgen call volume above normal and directionally bullish Feb 08 11:20pm ET Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and UnitedHealth (UNH) Feb 07 10:32am ET Amgen downgraded, Enphase upgraded: Wall Street’s top analyst calls Feb 07 10:25am ET Amgen Hold Rating Affirmed Amid Financial Outlook and Drug Pipeline Developments Feb 07 9:09am ET Amgen price target raised to $329 from $303 at RBC Capital Feb 07 8:21am ET Analysts’ Top Healthcare Picks: Amgen (AMGN), Qiagen (QGEN) Feb 07 7:38am ET Amgen price target raised to $380 from $350 at Oppenheimer Feb 07 7:35am ET Buy Rating Affirmed: Amgen’s Strong Q4 Performance and Promising 2024 Pipeline Outlook Feb 07 7:30am ET Amgen (AMGN) Gets a Buy from RBC Capital Feb 07 7:25am ET Amgen’s Stock Buoyed by Obesity Drug Prospects and Pipeline Developments Despite EPS Guidance and AMG-133 Concerns Feb 07 7:25am ET Hold Rating on Amgen Amid Uncertainty in Obesity Drug Efficacy and Competitive Concerns Feb 07 6:59am ET Amgen downgraded to Market Perform from Outperform at Leerink

No recent press releases are available for AMGN

AMGN Financials

1-year income & revenue

Key terms

AMGN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AMGN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms